PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...
More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved PTC's ...
See PTC Inc. (PTC) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results